Market Overview

UPDATE: Sterne Agee Reiterates Neutral Rating, Raises PT on ICON plc

Related ICLR
Cancer Genetics Inc. Announces a Partnership With ICON's Laboratory Services to Offer Comprehensive Oncology Laboratory Testing and Solutions
Jefferies Boosts Targets Across Pharmaceutical Service Stocks

In a report published Monday, Sterne Agee Group reiterated its Neutral rating on ICON plc (NASDAQ: ICLR), and slightly raised its price target from $24.00 to $25.00.

Sterne Agee noted, “Not unlike our caution on PRXL, we must question ICLR's ability to provide accurate forecasts. However, ICLR's forecasting and cost management skills have proven quite conservative over the years. ICLR is projecting EBIT margins to return to levels achieved a few years back, while PRXL is projecting 2-3 year margins never achieved by the company. We use a 15x multiple on our CY14 EPS estimate to arrive at a $25 price target, which compares to an average 17x over the past 10 years.”

ICON plc closed on Friday at $28.29.

Latest Ratings for ICLR

Oct 2015Avondale PartnersInitiates Coverage onMarket Perform
Aug 2015Credit SuisseAssumesOutperform
Jul 2015KeyBancReiteratesOverweight

View More Analyst Ratings for ICLR
View the Latest Analyst Ratings

Posted-In: Sterne Agee GroupAnalyst Color Price Target Analyst Ratings


Related Articles (ICLR)

Get Benzinga's Newsletters